Seroatlas · Human Serome Atlas

CT62

Cancer/testis antigen 62

Also known as: CT62_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P0C5K7
Gene: CT62
Canonical length: 136 aa

OverviewNCBI Gene

No narrative summary is available for CT62 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

136 residues, UniProt reviewed canonical sequence.

>P0C5K7|CT62
     1  MMHTTSYRRL SPPHLTDQPS AYSHTHRTFS HFSCGSQPAA QRLHVELWNA DLQSEFLCPC
    61  LGLTLYLTCN PQLGKRKFCS HSSEDMSKMV SRRNVKDSHE VSGSLQATLQ VISFSFPFLL
   121  HTCSHPLSHP TSGQRR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CT62 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.67

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.93
gnomAD pLI: 0.02
gnomAD missense Z: -0.12

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CT62 as an antibody target. Whether an autoantibody or antibody against CT62 could matter depends on whether native CT62 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CT62 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CT62 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...